〔Abstract〕 Objective To study the clinical effect of edaravone in the treatment of acute cerebral infarction with aspirin. Methods 63 patients with acute cerebral infarction treated in Xuchang Central Hospital from January 2019 to January 2021 were selected and divided into a control group (31 cases) and an observation group (32 cases) by random number method. Both groups were given conventional treatment such as anticoagulation and thrombolysis, the control group was given aspirin enteric-coated tablet on the basis of conventional treatment, and the observation group was given edaravone on the basis of the control group. The efficacy, neurovascular injury markers [homocysteine (Hcy), neurone specific enolase (NSE), central nervous system specific protein β (S100-β)], inflammatory factors [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) before treatment and 2 weeks after treatment were compared between the two groups and the occurrence of adverse drug reactions. Results The total effective rate of the observation group was 93.75 %, higher than that of the control group (70.97 %), the difference was statistically significant (P < 0.05). After treatment, the levels of Hcy, S100-β, NSE, CRP, IL-6 and TNF-α in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Edaravone combined with aspirin was used to treat patients with acute cerebral infarction, it can improve the damage of nerve blood vessels in patients, reduce inflammatory response, low incidence of adverse reactions, and high safety.